RecruitingPhase 2NCT03991832

Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors

Studying Glial tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Health Network, Toronto
Principal Investigator
Eric Chen, M.D., MD
Princess Margaret Cancer Centre
Intervention
Olaparib(drug)
Enrollment
58 target
Eligibility
18 years · All sexes
Timeline
20192025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03991832 on ClinicalTrials.gov

Other trials for Glial tumor

Additional recruiting or active studies for the same condition.

See all trials for Glial tumor

← Back to all trials